Four Months of Fingolimod Does Not Improve Anxiety or Depression in MS

Fingolimod is an established oral disease-modifying therapy for relapsing-remitting multiple sclerosis, with demonstrated efficacy in reducing relapse rates and magnetic resonance imaging lesion activity compared to injectable interferon beta-1a [1]. Its use, however, requires balancing these neurological benefits against a known risk profile, including a modest increase in the incidence of respiratory and herpes virus infections [2]. Beyond its primary immunomodulatory effects, a critical question for clinicians is whether this therapy also impacts the significant burden of psychiatric comorbidities common in multiple sclerosis. Some previous analyses have suggested that a switch to fingolimod is associated with an improvement in depressive symptoms [3]. This observation has raised the possibility that the drug's benefits may extend beyond physical endpoints, prompting further investigation into its direct or indirect effects on patient mood and anxiety.